UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving EDAP TMS S.A. and a Lead Plaintiff Deadline of October 3, 2014 -- EDAP

NEW YORK, Aug. 12, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased EDAP TMS S.A. ("EDAP" or the "Company") EDAP securities between February 1, 2013 and July 30, 2014.

Click here to learn about the case: http://docs.wongesq.com/EDAP-Info-Request-Form-350. There is no cost or obligation to you.

The complaint alleges that during the Class Period the Company made false and/or misleading statements regarding its Ablatherm-HIFU device. In particular it is alleged that the Company made false and/or misleading statements and/or failed to disclose that: (a) the Company overstated the efficacy and safety of its Ablatherm trials by relying on cross-study comparisons rather than a head-to-head trial; (b) the study's survival endpoint was inappropriate for the patient populations; and (c) as a result of the aforementioned, the Company's statements regarding its business and operations were materially false and misleading at all relevant times.

On July 30, 2014, the FDA announced that a panel found EDAP had failed to demonstrate the efficacy of its product or that the benefits of the device outweighed its risks.

If you suffered a loss in EDAP you have until October 3, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/EDAP-Info-Request-Form-350.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.